CLINICAL RESPONSE AT WEEK 52 AND COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING BIOLOGICAL THERAPY IN A SPECIALIZED CENTER IN COLOMBIA
OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with a prevalence of 1% in general population. Due to the course of disease patients have progressive disability that causes productivity losses and early retirement leading to great expenses for society. Biological treatment for...
Saved in:
Published in | Value in health Vol. 20; no. 5; p. A144 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Lawrenceville
Elsevier Science Ltd
01.05.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with a prevalence of 1% in general population. Due to the course of disease patients have progressive disability that causes productivity losses and early retirement leading to great expenses for society. Biological treatment for RA has been proved as an effective treatment but it is associated with high costs. We describe the costs of biological therapy in patients with RA in a specialized center. METHODS: We conducted a real-world, retrospective, cross-sectional study, we included patients with biological therapy; they were followed-up during 52 weeks and treated according to Disease Activity Score 28 (DAS28). Descriptive epidemiology was done; means were analyzed using t-Student performing a normality test for DAS28 and overall therapy costs were assessed. RESULTS: 684 patients were included; mean DAS28 at begining of therapy was 3.1 ± 1.1; the majority of patients received Adalimumab 16% followed by Etanercept 25 mg 12%, Tocilizumab, Infliximab and Rituximab 11%, Abatacept IV 10%, Etanercept 50 mg 10%, Certolizumab and Golimumab 7%, Tofacitinib 3% and Abatacept SC 2%. The most expensive biologic treatment was Golimumab (USD 12.770/year) followed by Certolizumab (USD 10.357), Etanercept 25 mg and 50 mg (USD 10.347), Tofacitinib (USD 9.811) Adalimumab ( USD 9.799), Abatacept SC (USD 9.656) Tocilizumab ( USD 8.795). Abatacept IV (USD 8.330 Infliximab (USD 6.564) and Rituximab (USD 4.427). When the progression of the disease was compared at week 52, most of patients went from a DAS28 of 3.1 ± 1.1 to a mean DAS28 of 2.4 ± 0.8 using biological therapy. CONCLUSIONS: The use of biologic therapies in the treatment of RA is effective but continues to be associated with high costs of biological therapy is to carefully evaluate patients that will receive this medications, nonetheless further research based on cost-effectiveness analysis is needed to verify these results.20 |
---|---|
AbstractList | OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with a prevalence of 1% in general population. Due to the course of disease patients have progressive disability that causes productivity losses and early retirement leading to great expenses for society. Biological treatment for RA has been proved as an effective treatment but it is associated with high costs. We describe the costs of biological therapy in patients with RA in a specialized center. METHODS: We conducted a real-world, retrospective, cross-sectional study, we included patients with biological therapy; they were followed-up during 52 weeks and treated according to Disease Activity Score 28 (DAS28). Descriptive epidemiology was done; means were analyzed using t-Student performing a normality test for DAS28 and overall therapy costs were assessed. RESULTS: 684 patients were included; mean DAS28 at begining of therapy was 3.1 ± 1.1; the majority of patients received Adalimumab 16% followed by Etanercept 25 mg 12%, Tocilizumab, Infliximab and Rituximab 11%, Abatacept IV 10%, Etanercept 50 mg 10%, Certolizumab and Golimumab 7%, Tofacitinib 3% and Abatacept SC 2%. The most expensive biologic treatment was Golimumab (USD 12.770/year) followed by Certolizumab (USD 10.357), Etanercept 25 mg and 50 mg (USD 10.347), Tofacitinib (USD 9.811) Adalimumab ( USD 9.799), Abatacept SC (USD 9.656) Tocilizumab ( USD 8.795). Abatacept IV (USD 8.330 Infliximab (USD 6.564) and Rituximab (USD 4.427). When the progression of the disease was compared at week 52, most of patients went from a DAS28 of 3.1 ± 1.1 to a mean DAS28 of 2.4 ± 0.8 using biological therapy. CONCLUSIONS: The use of biologic therapies in the treatment of RA is effective but continues to be associated with high costs of biological therapy is to carefully evaluate patients that will receive this medications, nonetheless further research based on cost-effectiveness analysis is needed to verify these results.20 |
Author | Castro, C Jaimes, J Villarreal, L Jaimes, H Aza, A Buitrago-Garcia, D Santos-Moreno, P |
Author_xml | – sequence: 1 givenname: P surname: Santos-Moreno fullname: Santos-Moreno, P – sequence: 2 givenname: L surname: Villarreal fullname: Villarreal, L – sequence: 3 givenname: A surname: Aza fullname: Aza, A – sequence: 4 givenname: H surname: Jaimes fullname: Jaimes, H – sequence: 5 givenname: J surname: Jaimes fullname: Jaimes, J – sequence: 6 givenname: C surname: Castro fullname: Castro, C – sequence: 7 givenname: D surname: Buitrago-Garcia fullname: Buitrago-Garcia, D |
BookMark | eNqNjM1OwkAUhScGE0F9AVc3cd16p2VaWA7DQG8s02ZmCNENYVEXDWmViu_gWzsYH8DVOTk_34SNur5rGHvgGHPk2VMbt1-HY5wgz2MUMaK4YmMukmk0zdN0FDzOZ1GKXNywyTC0iJiliRizb1WSISVLsNrVlXEapIed1s8gEpBmCapy3gEZqKUnbYLfkS_AFnq7kb6iJUjrC0ueHGwdmTUsqCqr9S_UF9rK-uVyl-BqrUiW9KoDNZC0veQqjDcLknfs-u1wHJr7P71ljyvtVRG9n_qPczN87tv-fOpCtU9wnmeZyMUs_d_qB6QZT1w |
ContentType | Journal Article |
Copyright | Copyright Elsevier Science Ltd. May 2017 |
Copyright_xml | – notice: Copyright Elsevier Science Ltd. May 2017 |
DBID | 7QJ |
DOI | 10.1016/j.jval.2017.05.005 |
DatabaseName | Applied Social Sciences Index & Abstracts (ASSIA) |
DatabaseTitle | Applied Social Sciences Index and Abstracts (ASSIA) |
DatabaseTitleList | Applied Social Sciences Index and Abstracts (ASSIA) |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1524-4733 |
GeographicLocations | Colombia |
GeographicLocations_xml | – name: Colombia |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 0SF 123 1OC 1P~ 1~. 29Q 36B 4.4 457 4G. 51W 51X 52N 52P 52R 52X 53G 5LA 5VS 66C 6I. 6PF 7-5 7PT 7QJ 8-1 8P~ 8UM AACTN AAEDT AAEDW AAFJI AAFTH AAFWJ AAIKJ AAKOC AALRI AAOAW AAPFB AAQFI AAWTL AAXKI AAXUO ABBQC ABCQN ABEML ABIVO ABJNI ABMAC ABMMH ABMZM ABVKL ACDAQ ACGFS ACHQT ACPRK ACRLP ADBBV ADEZE ADFHU ADVLN AEBSH AEKER AENEX AEQDE AEVXI AEXQZ AEYQN AFCTW AFEBI AFKWA AFRHN AFTJW AFXIZ AGTHC AGUBO AGYEJ AIEXJ AIIAU AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AOMHK AVARZ AXJTR AXLSJ BAWUL BKOJK BLXMC BNPGV CS3 DIK DU5 EBS EFJIC EJD EMB ESX F5P FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZI IXB KOM M41 MO0 N9A NCXOZ O-L O9- OAUVE OIG OK1 P-8 P-9 P2P PC. PQQKQ PRBVW Q38 RIG ROL SDF SEL SES SPCBC SSB SSF SSH SSO SSZ SUPJJ T5K W99 YFH Z5R ~G- |
ID | FETCH-proquest_journals_20976657583 |
ISSN | 1098-3015 |
IngestDate | Sun Sep 29 03:07:59 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-proquest_journals_20976657583 |
PQID | 2097665758 |
PQPubID | 105593 |
ParticipantIDs | proquest_journals_2097665758 |
PublicationCentury | 2000 |
PublicationDate | 20170501 |
PublicationDateYYYYMMDD | 2017-05-01 |
PublicationDate_xml | – month: 05 year: 2017 text: 20170501 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Lawrenceville |
PublicationPlace_xml | – name: Lawrenceville |
PublicationTitle | Value in health |
PublicationYear | 2017 |
Publisher | Elsevier Science Ltd |
Publisher_xml | – name: Elsevier Science Ltd |
SSID | ssj0006325 |
Score | 4.386175 |
Snippet | OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with a prevalence of 1% in general population. Due to the course of disease patients have... |
SourceID | proquest |
SourceType | Aggregation Database |
StartPage | A144 |
SubjectTerms | Autoimmune diseases Cost analysis Disability Early retirement Epidemiology Etanercept Immunotherapy Infliximab Monoclonal antibodies Normality Patients Productivity Rheumatoid arthritis Rituximab Tumor necrosis factor-α |
Title | CLINICAL RESPONSE AT WEEK 52 AND COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING BIOLOGICAL THERAPY IN A SPECIALIZED CENTER IN COLOMBIA |
URI | https://www.proquest.com/docview/2097665758/abstract/ |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEuFRQQj4JGAvXiJnLt9SPHrdniLYljJZsSuES2caRWVSrlcWgP3Dnzh5n1-gVFFXBZrdbx2sl8mZ2dnW-GkHcW9XMnt7JuYi-Ut2phd_smNmmS5V_7pp8nxYnpMHLDKT2dObNO50cramm7SXvZzR95Jf8jVRxDuSqW7D9Itp4UB7CP8sUWJYztX8k4GIioyGeAP2M8iibcYLg_5_yj4VhF3qhgNJGKI2zETAoeYf-TkKExDvl0yORIvDfQng3HQoqJoQpwfDCORV0eQYZ8zOLP6nZmTGIeCDYQXzjOylUeXTUe4IeHx4K1Tdyz5HJbZCLRFMvahaOqFa-7w6tVXlT7bohlZ6rw0QqN18uGBaEgeJP84ms9Tc5L8kTYdlXg8lcHBmr_WcWhqdRWE7ikVK_KbIrqRp9x56U6tmiXejpVRqWvLbOFS6elfNmRTiV5a1XQDoqL3gWKWEXz6WStptOsgdW5fzSan0wHg7nkM3mP3Le8vqN29L1vTdyQaxeVfOvXLZlYOmjw9yfcWuELs0U-IrvlfgOYBs9j0smXe-TBsIyo2CMHsc5dfn0IsqHirQ_hAOImq_n1E_K9AhtUYAMmQYENHAsQbFCADUQEFdhAgQ0asEENNijABg3YoASbup1BC2ygwabGK7A9JW9PuAzCbvWd5-WfZT23TLR71SGfbz8jO8urZf6cgOt6KU19uqA0pUc08W3fz7M081KPprbtviD7d8308u7Lr8jDBoT7ZGez2uav0YLcpG8Kif4E4txgiQ |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CLINICAL+RESPONSE+AT+WEEK+52+AND+COSTS+IN+PATIENTS+WITH+RHEUMATOID+ARTHRITIS+USING+BIOLOGICAL+THERAPY+IN+A+SPECIALIZED+CENTER+IN+COLOMBIA&rft.jtitle=Value+in+health&rft.au=Santos-Moreno%2C+P&rft.au=Villarreal%2C+L&rft.au=Aza%2C+A&rft.au=Jaimes%2C+H&rft.date=2017-05-01&rft.pub=Elsevier+Science+Ltd&rft.issn=1098-3015&rft.eissn=1524-4733&rft.volume=20&rft.issue=5&rft.spage=A144&rft_id=info:doi/10.1016%2Fj.jval.2017.05.005&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-3015&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-3015&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-3015&client=summon |